New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPAR&ggr; Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|6|393-419

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.6, 2005-09, pp. : 393-419

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 8, Iss. 8, 2008-12 ,pp. : 647-665

Bentham Science Publishers

Access to resources Recommend Favorite

PPAR-&ggr; Agonists as Regulators of Microglial Activation and Brain Inflammation

By  

Current Pharmaceutical Design, Vol. 12, Iss. 1, 2006-01 ,pp. : 93-109

Bentham Science Publishers

Access to resources Recommend Favorite

The mTOR Pathway: A New Target in Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. : 484-495

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR inhibitors in the treatment of cancer

By Fasolo Angelica   Sessa Cristiana  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1717-1734

Informa Healthcare

Access to resources Recommend Favorite

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

By Wacheck Volker  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1189-1191

Future Medicine

Access to resources Recommend Favorite